论文部分内容阅读
[目的]探讨双时相门冬胰岛素50(BIAsp50)与双时相人胰岛素50(BHI50)治疗2型糖尿病(T2DM)的疗效及其对患者餐后2 h血糖(2hPG)、血清可溶性细胞间黏附因子(sICAM-1)、可溶性血管细胞黏附分子-1 (sVCAM-1)、单核细胞趋化蛋白-1(MCP-1)与肿瘤坏死因子-α(TNF-α)水平的影响.[方法]选取2016年1月至2017年1月本院收治的既往未行胰岛素治疗的66例T2DM患者为研究对象,随机分为BIAsp50组与BHI50组各33例.分别给予BIAsp50、BHI50每日两次皮下注射.比较两组治疗前后的空腹血糖(FPG)、2hPG及增幅、餐后2 h内的增幅曲线下面积(IAUC)及糖化血红蛋白(HbA1c),以及血清sICAM-1、sVCAM-1、MCP-1和TNF-α等炎症指标的水平.[结果]①治疗前,两组血糖水平各指标(FPG、2hPG、2hPG的振幅、IAUC及 HbA1c)比较,差异均无统计学意义(P>0.05).治疗后6、12周,两组各个血糖指标均显著降低(P<0.05);BIAsp50组治疗后6、12周的2hPG、2hPG的增幅、2 h内的 IAUC均显著低于BHI50组;治疗后12周的 HbA1c显著低于BHI50组,差异均有统计学意义(P< 0.05).②BIAsp50组低血糖事件的总发生率为12.1%,显著低于BHI50组的33.3%,差异均有统计学意义(P0.05).治疗后6、12周,两组的各个炎症指标均显著降低(P<0.05);组间比较,BIAsp50组治疗后12周的各炎症指标均显著低于BHI50组,治疗后6周的sVCAM-1、TNF-α显著低于BHI50组,差异均有统计学意义(P0.05).⑵ At 6 and 12 weeks after treatment,plasma glu-cose level were significantly decreased in the two groups(P 0.05).2hPG and its increment,IAUC within postprandial 2h in the BIAsp50 group at 6 and 12 weeks after treatment were significantly lower than those in BHI50 group,and HbA1c at 12 weeks after treatment was significantly lower than that in the BHI50 group(P <0.05).⑶ The total inci-dence of hypoglycemia in the BIAsp50 group was 12.1% and significantly lower than in the BHI50 group 33.3%(P 0.05).⑷At 6 and 12 weeks after treatment,serum levels of inflammatory markers were significant-ly decreased in the two groups(P <0.05).Serum levels of inflammatory markers in the BIAsp50 group at 6 and 12 weeks after treatment were significantly lower than those in the BHI50 group,and sICAM-1,MCP-1 at 12 weeks after treatment were significantly lower than those in the BHI50 group(P <0.05).[Conclusion]Compared with BHI50,BIAsp50 has better control effect on postprandial plasma glucose in patients with T 2DM,and can de-crease the incidence of hypoglycemia,and serum levels of sICAM-1,sVCAM-1,MCP-1 and TNF-α were lower, thus the improvement of injury of vascular endothelial cells and inflammation response is more prominent.